EMA Acceptance for Blarcamesine
The European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) for blarcamesine for the treatment of Alzheimer's disease. This submission is backed by data from the Phase IIb/III ANAVEX-004 trial and a 144-week open-label extension entitled study ATTENTION-AD, potentially bringing the company closer to offering a new treatment option in Europe.
Upcoming Presentation at JPMorgan 2025 Healthcare Conference
Anavex announced its upcoming presentation of top line long-term data from the ATTENTION-AD open-label extension trial at the JPMorgan 2025 Healthcare Conference in January 2025.
Publication of Blarcamesine Data
A peer-reviewed manuscript titled blarcamesine for the treatment of early Alzheimer's disease from the ANAVEX2-73-AD-004 Phase II/III trial has been accepted for publication in a medical journal focused on Alzheimer's disease.
Encouraging Preliminary EEG Biomarker Results for ANAVEX 3-71
Anavex announced encouraging preliminary EEG biomarker results from Part A of the ongoing placebo-controlled Phase II clinical study of ANAVEX 3-71 for the treatment of schizophrenia, demonstrating a dose-dependent effect on two key EEG biomarkers.
Strong Financial Position
Anavex reported a cash position of $132.2 million with no debt, and a cash utilization rate indicating a runway of approximately 4 years.